FDA: Hospira recalls one lot of Sodium Bicarbonate Injection

Editor's Note

The Food and Drug Administration (FDA) on March 21 announced the recall by Hospira, Inc (Lake Forest, Illinois) of one lot of 8.4% Sodium Bicarbonate Injection, USP (NDC: 0409-6625-02, Lot 56-148-EV, Expiry August 1, 2017).

The recall was initiated because of the presence of a particulate in a single-dose glass fliptop vial. The lot was distributed in December 2015.

Administration of product with particulates may result in localized inflammation, allergic reaction including anaphylaxis, granuloma formation, microembolic effects, or delay of therapy.